Mier JW - Search Results

1

Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy.

Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H. Vannier E, et al. Among authors: mier jw. Eur Cytokine Netw. 1999 Mar;10(1):37-42. Eur Cytokine Netw. 1999. PMID: 10210771 Free article. Clinical Trial.

2

Suppression of IL-2-induced SAA gene expression in mice by the administration of an IL-1 receptor antagonist.

Numerof RP, Sipe JD, Trehu EG, Dinarello CA, Mier JW. Numerof RP, et al. Among authors: mier jw. Cytokine. 1992 Nov;4(6):555-60. doi: 10.1016/1043-4666(92)90019-n. Cytokine. 1992. PMID: 1292638

3

Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans.

Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, Catalano MA, Wolff SM, Dinarello CA. Granowitz EV, et al. Among authors: mier jw. Cytokine. 1992 Sep;4(5):353-60. doi: 10.1016/1043-4666(92)90078-6. Cytokine. 1992. PMID: 1420996 Clinical Trial.

4

Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans.

Tilg H, Trehu E, Shapiro L, Pape D, Atkins MB, Dinarello CA, Mier JW. Tilg H, et al. Among authors: mier jw. Cytokine. 1994 Mar;6(2):215-9. doi: 10.1016/1043-4666(94)90044-2. Cytokine. 1994. PMID: 8032003 Clinical Trial.

5

Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55.

Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Tilg H, et al. Among authors: mier jw. Blood. 1994 Jan 1;83(1):113-8. Blood. 1994. PMID: 8274730 Free article. Clinical Trial.

6

A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy.

Tilg H, Pape D, Trehu E, Shapiro L, Atkins MB, Dinarello CA, Mier JW. Tilg H, et al. Among authors: mier jw. J Immunol Methods. 1993 Aug 9;163(2):253-8. doi: 10.1016/0022-1759(93)90129-u. J Immunol Methods. 1993. PMID: 8354894 Clinical Trial.

7

Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble tumor necrosis factor receptor (p75) chimera.

Tilg H, Shapiro L, Atkins MB, Dinarello CA, Mier JW. Tilg H, et al. Among authors: mier jw. J Immunol. 1993 Sep 15;151(6):3299-307. J Immunol. 1993. PMID: 8397255

8

Induction of circulating IL-1 receptor antagonist by IFN treatment.

Tilg H, Mier JW, Vogel W, Aulitzky WE, Wiedermann CJ, Vannier E, Huber C, Dinarello CA. Tilg H, et al. Among authors: mier jw. J Immunol. 1993 May 15;150(10):4687-92. J Immunol. 1993. PMID: 8482853 Clinical Trial.

9

Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapy.

Tilg H, Atkins MB, Dinarello CA, Mier JW. Tilg H, et al. Among authors: mier jw. Cytokine. 1995 Oct;7(7):734-9. doi: 10.1006/cyto.1995.0087. Cytokine. 1995. PMID: 8580384 Clinical Trial.

10

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.

Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB. Du Bois JS, et al. Among authors: mier jw. J Clin Oncol. 1997 Mar;15(3):1052-62. doi: 10.1200/JCO.1997.15.3.1052. J Clin Oncol. 1997. PMID: 9060545 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

159 results

Search Page

Filters